Table 3

Details of study outcomes, time points and a summary of results

AuthorYearOutcomes (primary in italics if present)Time pointsEffect measures—mean difference (95% CI) in short term, medium term, long termSummary of results and adverse events
Bahadir et al122009VAS (activity), tip pinch strength, grip strength, Duruoz Hand IndexBaseline, 1 month, 3 months, 6 months, 12 monthsVAS (activity) −1.60 (−3.21 to 0.01), −2.20 (−3.45 to –0.95), −1.10 (−2.37 to 0.17)
Tip pinch strength 1.90 (0.60 to 3.20), 1.10 (−0.17 to 2.37), 1.10 (−0.11 to 2.31)
Grip strength 9.60 (2.03 to 17.17), 6.40 (−0.05 to 12.85), 4.80 (−2.46 to 12.06)
Duruoz Hand Index −10.20 (−17.24 to –3.16), −10.10 (−16.77 to –3.43), −3.80 (−11.57 to 3.97)
Greater statistically significant improvement in VAS with corticosteroid than with hyaluronic acid at 1 month and 6 months. No adverse events.
Figen Ayhan and Ustün162009VAS (average of rest/activity/pressure), tip pinch strength, tripod pinch strength, key pinch strength, Dreiser IndexBaseline, 6 weeks, 6 monthsNot estimable from available dataNo statistically significant difference in outcomes at any time point. No adverse events.
Fuchs et al132006VAS pain, tip pinch strength, key pinch strength, range of movementBaseline, 3 weeks, 14 weeks, 26 weeksNot estimable from available dataStatistically significant superiority of corticosteroid over hyaluronic acid at 2 and 3 weeks time point in terms of pain relief. No causal adverse events.
Heyworth et al172008VAS pain, tip pinch strength, grip strength, key pinch strength, DASH, range of motion (MCPJ)Baseline, 2 weeks, 4 weeks, 12 weeks, 26 weeksNot estimable from available dataNo statistically significant difference between groups at most time points. No adverse events.
Jahangiri et al182014VAS (pressure), lateral pinch strength, VAS (activity), hand function (HAQ-DI)Baseline, 1 month, 2 months, 6 monthsVAS (pressure) data not provided for short term, 1.1 (0.2 to –2.0) in medium term
VAS (activity) 1.0 (0.1 to 2.0), 1.1 (0.2 to 2.0)
Lateral pinch strength 1.1 (−0.8 to 3.1), 0.8 (−1.3 to 2.9)
HAQ-DI 1.0 (0.2 to 1.9), 1.0 (0.2 to 1.8)
Corticosteroid group had statistically significant reduction in VAS (pressure) at 1 month vs dextrose, while dextrose demonstrated statistically significant reduction in VAS (pressure) at 6 months vs corticosteroid. No adverse events.
Meenagh et al192004VAS (pain), joint tenderness, patient global assessment, physician global assessment, joint stiffnessBaseline, 1 month, 3 months, 6 monthsJoint tenderness −1.00 (−1.80 to –0.20), −2.00 (−3.92 to –0.08)
Patient global assessment −2.00 (−3.92 to –0.08), −2.00 (−3.92 to –0.08)
Physician global assessment −2.00 (−3.92 to –0.08), −1.00 (−1.27 to –0.73)
Joint stiffness −1.00 (−1.27 to –0.73), −1.00 (−1.27 to –0.73)
VAS (pain) not estimable from available data
No statistically significant difference between groups at all time points. No adverse events.
Monfort et al142015VAS (rest), Dreiser Index, PCS-36, MCS-36Baseline, 1 week, 2 weeks, 1 month, 2 months, 6 monthsVAS (rest) −0.56 (−1.58 to 0.46), 0.55 (−0.51 to 1.61)
Dreiser Index 0.00 (−2.24 to 2.24), not estimable from available data at medium term
PCS-36 0.00 (−2.24 to 2.24) at medium term
MCS-36 0.00 (−2.24 to 2.24) at medium term
No statistically significant difference between groups at all time points in VAS and Dreiser Index. No adverse events.
Roux et al202007VAS (rest), Dreiser IndexBaseline, 1 month, 3 monthsHA1 vs HA2
VAS (rest) −1.90 (−21.48 to 17.68), 3.60 (−16.60 to 23.80)
Dreiser Index −1.70 (−7.71 to 4.31), 0.00 (−2.24 to 2.24)
HA1 vs HA3
VAS (rest) −0.06 (−0.84 to 0.73), 3.60 (−16.60 to 23.80)
Dreiser Index −1.70 (−7.71 to 4.31), −1.70 (−7.71 to 4.31)
HA2 vs HA3
VAS (rest) 0.53 (−0.29 to 1.34), 0.53 (−0.29 to 1.34)
Dreiser Index −1.70 (−7.71 to 4.31), −1.70 (−7.71 to 4.31)
No statistically significant difference in outcomes between groups at all time points. No adverse events.
Stahl et al152005Tip pinch strength, tripod pinch strength, key pinch strength, grip strength, VAS (rest), VAS (activity)Baseline, 1 month, 3 months, 6 monthsVAS (activity) 0.35 (−0.90 to 1.60), −0.30 (−1.64 to 1.04)
VAS (rest) −0.27 (−0.81 to 0.28), 0.25 (−1.09 to 1.59)
Tip pinch strength −0.77 (−1.43 to –0.11), −0.33 (−0.96 to 0.30)
Tripod pinch strength −0.79 (−1.72 to 0.14), −0.45 (−1.34 to 0.44)
Key pinch strength −1.19 (−2.43 to 0.05), −1.02 (−2.14 to 0.10)
Grip strength −0.33 (−0.96 to 0.30), −0.33 (−0.96 to 0.30)
No statistically significant difference in outcomes between groups at all time points. No adverse events.
  • DASH, Disabilities of the Arm, Shoulder and Hand; HA1, one HA injection group; HA2, two HA injections group; HAQ-DI, Health Assessment Questionnaire - Disability Index; MCPJ, metacarpophalangeal joint; MCS, mental component summary of the SF-36; PCS, physical component summary of the SF-36; SF-36, short form 36 health survey; VAS, Visual Analogue Scale.